scholarly journals Effects of Intermittent Pneumatic Compression on Reduction of Postoperative Lower Extremity Edema and Normalization of Foot Microcirculation Flow in Patients Undergoing Arterial Revascularization

2015 ◽  
Vol 21 ◽  
pp. 3986-3992 ◽  
Author(s):  
Katarzyna Pawlaczyk ◽  
Marcin Gabriel ◽  
Tomasz Urbanek ◽  
Łukasz Dzieciuchowicz ◽  
Zbigniew Krasiński ◽  
...  
Keyword(s):  
Lower Extremity ◽  
Intermittent Pneumatic Compression ◽  
Lower Extremity Edema ◽  
Arterial Revascularization

The Effect of Lower Extremity Exercise Program on Lower Extremity Edema and Pain for Women Officers

2021 ◽  
Vol 29 (3) ◽  
pp. 409-414
Author(s):  
Kyoung-Bin Min ◽  
Myung-Sung Kang ◽  
Hyun Seo ◽  
Un-Hyo Baek ◽  
Yong-Gon Seo
Keyword(s):  
Lower Extremity ◽  
Exercise Program ◽  
Lower Extremity Edema ◽  
Women Officers

Abstract 18615: Impact of Peripheral Atherectomy Utilization on the Outcomes of Lower Extremity Arterial Intervention - A Cross-sectional US Experience

Circulation ◽  
2015 ◽  
Vol 132 (suppl_3) ◽  
Author(s):  
Shilpkumar Arora ◽  
Sopan Lahewala ◽  
Nilay Patel ◽  
Kanishk Agnihotri ◽  
Sidakpal Panaich ◽  
...  
Keyword(s):  
Multivariate Analysis ◽  
Lower Extremity ◽  
Arterial Intervention ◽  
Limb Ischemia ◽  
Outcome Data ◽  
Drug Eluting Stent ◽  
P Value ◽  
Diagnostic Code ◽  
Cross Sectional ◽  
Arterial Revascularization

Background: Contemporary outcome data regarding effects of atherectomy in lower extremity arterial revascularization is lacking. Methods: We queried HCUP’s Nationwide Inpatient Sample (NIS) for 2012 using the appropriate primary ICD 9-CM diagnostic code for peripheral vascular disease and procedural codes 39.90 (bare metal stent - BMS), 00.55 (drug eluting stent - DES), 17.56 (peripheral artherectomy) and 39.50 for angioplasty. Only procedures performed in patients >= 18 years were included. Hierarchical mixed effects logistic regression models were generated to evaluate multivariate predictors of outcomes. Results: In total 13,206 (weighted: 66,030) lower extremity arterial revascularization were analyzed (65.5% white, 56.2% Male & 97.4% angioplasty). Atherectomy utilization (23.2%) was associated with significant reduction in amputation (11.5% vs 13.4%), any complications (13.2% vs 16.3%) and in hospital morality (0.8% vs 1.4%) compared to no atherectomy group (p < 0.001). Multivariate analysis showed similar results with decrease amputation (OR, 95% CI; p - value) (0.83, 0.71 - 0.97, p = 0.02) and in hospital mortality/any complication (0.79, 0.69 - 0.90, p = 0.001) with atherectomy (similar results were observed with propensity score matching). “Atherectomy only” was utilized only in 2.3%. post-hoc analysis also shows better outcomes when atherectomy was used with either angioplasty or stenting (figure a & b). subgroup multivariate analysis shows significant reduction in amputation when atherectomy was utilized in chronic limb ischemia (0.74, 0.59 - 0.93, p = 0.01) and with angioplasty (0.72, 0.60 - 0.87, p = 0.001) and trend towards advantage while used along with stents but not reaching statistical significant. Conclusion: Lower extremity atherectomy utilization was associated with significant reduction in amputation and overall complication. We observed better outcomes when atherectomy was used in conjunction with angioplasty.

Abstract 17062: Reversible Golimumab Induced Cardiomyopathy - First Reported Case Report

Circulation ◽  
2021 ◽  
Vol 144 (Suppl_2) ◽  
Author(s):  
Mian Tanveer Ud Din ◽  
Michael Nestasie ◽  
John Balacko ◽  
Craig Alpert
Keyword(s):  
Lower Extremity ◽  
Troponin T ◽  
Inflammatory Diseases ◽  
Systolic Function ◽  
Left Ventricular ◽  
Tnf Alpha ◽  
Lower Extremity Edema ◽  
Ventricular Systolic Function ◽  
Immune Mediated ◽  
Biventricular Systolic Function

Case Presentation: An 80 year old female with medical history of hypertension, diabetes mellitus, chronic atrial fibrillation presented with four weeks of lower extremity edema and dyspnea. Notably, she had also been taking Golimumab for 6 months for Rheumatoid Arthritis (RA). Vital signs on presentations were: Temp:99 F, HR: 140bpm, BP: 105/64, oxygen saturation of 88% on room air. Physical exam revealed crackles at the mid lower lung fields bilaterally and 2+ lower extremity edema. EKG showed new ST inversions in lead 1, avF and V2. Troponin T was elevated to 0.11 ng/ml and proBNP was 21,246 pg/ml. Chest X Ray showed cardiomegaly with diffuse alveolar opacities. Transthoracic echocardiogram (TTE) revealed severely reduced left ventricular systolic function with LVEF of 25-29%, left ventricular regional wall hypokinesis and mildly reduced right ventricular systolic function. All findings were new compared to her last TTE 3 months prior, which showed preserved biventricular systolic function. Coronary angiography revealed no coronary artery disease. The patient was started on intravenous furosemide, and her home beta blocker and ARB were resumed. The patient’s Golimumab was discontinued given prior reports of TNF alpha inhibitor induced cardiomyopathy. Over the ensuing days, she was aggressively diuresed with improvement in oxygenation and ultimately discharged home. Three months after discontinuation of Golimumab, repeat TTE showed normalization of biventricular systolic function. Discussion: TNF alpha inhibitors have revolutionized the treatment of chronic immune mediated inflammatory diseases. Several TNF alpha inhibitors have been associated with cardiomyopathy, however there remains a paucity of evidence regarding cardiotoxicity with Golimumab. We now present, to our knowledge, the first reported case of reversible heart failure due to Golimumab in an 80 year old woman with RA. Golimumab, like other TNF alpha inhibitors, represents a historic advancement in the treatment of immune mediated inflammatory diseases. However, our case implicates this innovative drug in cardiotoxicity similar to other TNF alpha inhibitors. Further prospective studies are needed to establish a stronger correlation between Golimumab and cardiotoxicity.

scholarly journals Dermatomyositis Sine Myositis with Membranoproliferative Glomerulonephritis

2012 ◽  
Vol 2012 ◽  
pp. 1-3 ◽  
Author(s):  
Mohammad Bagher Owlia ◽  
Roya Hemayati ◽  
Shokouh Taghipour Zahir ◽  
Mohammad Moeini Nodeh
Keyword(s):  
Mycophenolate Mofetil ◽  
Autoimmune Disease ◽  
Lower Extremity ◽  
Renal Biopsy ◽  
Membranoproliferative Glomerulonephritis ◽  
Pathological Examination ◽  
Lower Extremity Edema ◽  
History Of

Dermatomyositis (DM) is an autoimmune disease that is characterized by involvement of proximal musculature and skin. We report a 52-year-old woman with a 6-year history of dermatomyositis sine myositis, who developed lower extremity edema and proteinuria. Pathological examination of renal biopsy showed membranoproliferative glomerulonephritis. She received steroid, cyclophosphamide, and mycophenolate mofetil. Over the 9 to 10 months after the beginning of treatment, the proteinuria was improved.

Unilateral lower extremity edema caused by infiltrative sarcoidosis

1994 ◽  
Vol 30 (3) ◽  
pp. 498-500 ◽  
Author(s):  
Robert D. Hoover ◽  
George Stricklin ◽  
Trace W. Curry ◽  
Laurence C. Carmichael
Keyword(s):  
Lower Extremity ◽  
Lower Extremity Edema

Dyschromic Nails, Exertional Dyspnea, and Lower Extremity Edema

JAMA ◽  
2020 ◽  
Vol 324 (19) ◽  
pp. 1992
Author(s):  
Soumya Chatterjee ◽  
Elliott Chandler Dasenbrook
Keyword(s):  
Lower Extremity ◽  
Lower Extremity Edema ◽  
Exertional Dyspnea
Sign in / Sign up

Export Citation Format

Share Document